Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.
Randall Highlights Advances in Reconstruction Techniques for Patients With Bone Sarcomas
December 25th 2022Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.
Read More
Adagrasib Provides New Option for Patients with KRAS G12C–Mutant NSCLC
December 22nd 2022The FDA’s accelerated approval of adagrasib for adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer who have received at least 1 prior systemic therapy has provided a second KRAS G12C inhibitor option for patients.
Read More
Radiation Therapy Plus Surgery May Improve Local Control in Localized Pelvic Ewing Sarcoma
December 22nd 2022R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.
Read More
The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.
Read More
Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.
Read More
Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma
November 27th 2022Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.
Read More
Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022
November 21st 2022The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.
Read More
Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer
November 11th 2022As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.
Read More
Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment
November 10th 2022Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.
Read More
Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma
October 19th 2022The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1
Read More
Treatments for MCL Continue to Progress
October 14th 2022As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.
Read More
Abemaciclib Dose Reductions Lead to Prolonged Treatment in HR+/HER2- Breast Cancer
October 13th 2022Abemaciclib produced a clinically manageable safety profile in patients with hormone receptor–positive, HER2-negative, early breast cancer or advanced breast cancer, and dose reductions were found to effectively mitigate discontinuation.
Read More